Evaluation of published reports of foam sclerotherapy: what do we know conclusively?

被引:13
|
作者
Myers, K. A. [1 ]
Roberts, S. [1 ]
机构
[1] Victoria Vein Clin, Melbourne, Vic, Australia
关键词
foam sclerotherapy; varicose; veins; reticular; telangiectases; GREAT SAPHENOUS-VEIN; ULTRASOUND-GUIDED SCLEROTHERAPY; RANDOMIZED CONTROLLED-TRIAL; POLIDOCANOL FOAM; VARICOSE-VEINS; ENDOVENOUS LASER; DETERGENT SCLEROSANTS; EFFICACY; MICROEMBOLISM; STABILITY;
D O I
10.1258/phleb.2009.009048
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objectives: The aim was to evaluate the published literature to assess what is conclusively known about optimal technique and outcome for foam sclerotherapy. Methods: A literature search was performed for randomised controlled trials, meta-analyses and observational studies using appropriate statistical techniques with survival analysis for long-term outcome. Results: Foam is more effective than liquid for ultrasound-guided sclerotherapy. Both sclerosants commonly used are equally effective for sclerotherapy for small veins. Ultrasound signals appear in the systemic circulation in most patients after foam sclerotherapy but do not appear to be associated with serious complications. Conclusion: Little else is known about the optimal preparation of foamed sclerosants and the best technique for administering foam for sclerotherapy. Long-term studies are required to determine outcome for various techniques. There is an opportunity for many controlled trials to assess results.
引用
收藏
页码:275 / 280
页数:6
相关论文
共 50 条
  • [21] Simulation of colorectal cancer screening: What we do and do not know and does it matter
    van Ballegooijen, Marjolein
    Boer, Rob
    Zauber, Ann G.
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2010, 24 (04) : 427 - 437
  • [22] COVID-19 in dental care: What do we know?
    Chmielewski, Marek
    Zalachowska, Oliwia
    Rybakowska, Weronika
    Komandera, Dominika
    Knura, Agata
    Albert, Adrian
    Kostanowicz, Julia
    Garbacz, Katarzyna
    JOURNAL OF ORAL MICROBIOLOGY, 2021, 13 (01)
  • [23] Drug Transfer to the Fetus and to the Breastfeeding Infant: What Do We Know?
    Bernick, Steven J.
    Kane, Sunanda
    CURRENT DRUG DELIVERY, 2012, 9 (04) : 350 - 355
  • [24] Treating Postpartum Depression: What Do We Know about Brexanolone?
    Ali, Muneeza
    Aamir, Alifiya
    Diwan, Mufaddal Najmuddin
    Awan, Hashir Ali
    Ullah, Irfan
    Irfan, Muhammad
    De Berardis, Domenico
    DISEASES, 2021, 9 (03)
  • [25] What do we really know about mindfulness and sleep health?
    Ong, Jason C.
    Moore, Cameron
    CURRENT OPINION IN PSYCHOLOGY, 2020, 34 : 18 - 22
  • [26] Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi, Eihab A.
    Krulig, Eliana
    Gordon, Kenneth B.
    DERMATOLOGIC THERAPY, 2009, 22 (05) : 431 - 440
  • [27] Positive Affect and Health: What Do We Know and Where Next Should We Go?
    Pressman, Sarah D.
    Jenkins, Brooke N.
    Moskowitz, Judith T.
    ANNUAL REVIEW OF PSYCHOLOGY, VOL 70, 2019, 70 : 627 - 650
  • [28] COVID-19 vaccines: what do we know so far?
    Dhillon, Paraminder
    Altmann, Daniel
    Male, Victoria
    FEBS JOURNAL, 2021, 288 (17) : 4996 - 5009
  • [29] Pirfenidone use in fibrotic diseases: What do we know so far?
    Torre, Aldo
    David Martinez-Sanchez, Froylan
    Mercedes Narvaez-Chavez, Sofia
    Ariel Herrera-Islas, Mariana
    Alberto Aguilar-Salinas, Carlos
    Cordova-Gallardo, Jacqueline
    IMMUNITY INFLAMMATION AND DISEASE, 2024, 12 (07)
  • [30] Administration regimens for sublingual immunotherapy to pollen allergens: What do we know?
    Lombardi, C.
    Incorvaia, C.
    Braga, M.
    Senna, G.
    Canonica, G. W.
    Passalacqua, G.
    ALLERGY, 2009, 64 (06) : 849 - 854